Recombinant Human Siglec-3/CD33 His-tag Protein, CF Summary
Product Specifications
The ED50 for this effect is 0.1-0.8 µg/mL.
Met17-His259, with a C-terminal 6-His tag
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
10375-SL
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. |
Reconstitution | Reconstitute at 500 μg/mL in PBS. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
![Recombinant Human Siglec-3/CD33 His-tag Protein Bioactivity Recombinant Human Siglec-3/CD33 His-tag Protein Bioactivity](https://aeroglobalimagesuat.blob.core.windows.net/images/datasheets/protein/Siglec3_10375SL_3106.jpg)
Recombinant Human Siglec-3/CD33 His-tag (Catalog # 10375-SL) supports the adhesion of human red blood cells. The ED50 for this effect is 0.1-0.8 μg/mL.
![Recombinant Human Siglec-3/CD33 His-tag Protein SDS-PAGE Recombinant Human Siglec-3/CD33 His-tag Protein SDS-PAGE](https://aeroglobalimagesuat.blob.core.windows.net/images/datasheets/protein/Siglec3_10375SL_2965.jpg)
2 μg/lane of Recombinant Human Siglec-3/CD33 His-tag (Catalog # 10375-SL) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 44-55 kDa.
Reconstitution Calculator
Background: Siglec-3/CD33
Siglecs (sialic acid binding Ig-like lectins) are I-type (Ig-type) lectins belonging to the Ig superfamily. They are characterized by an N-terminal Ig-like V-type domain which mediates sialic acid binding, followed by varying numbers of Ig-like C2-type domains (1, 2). Eleven human Siglecs have been cloned and characterized. They are sialoadhesin/CD169/Siglec-1, CD22/Siglec-2, CD33/Siglec-3, Myelin-Associated Glycoprotein (MAG/Siglec-4a) and Siglecs 5 to 11 (1-3). To date, no Siglec has been shown to recognized any cell surface ligand other than sialic acids, suggesting that interactions with glycans containing this carbohydrate are important in mediating the biological functions of Siglecs. Siglecs 5 to 11 share a high degree of sequence similarity with CD33/Siglec-3 both in their extracellular and intracellular regions. They are collectively referred to as CD33-related Siglecs. One remarkable feature of the CD33-related Siglecs is their differential expression pattern within the hematopoietic system (1, 2). This fact, together with the presence of two conserved immunoreceptor tyrosine-based inhibition motifs (ITIMs) in their cytoplasma tails, suggests that CD33related Siglecs are involved in the regulation of cellular activation within the immune system. Human Siglec-3 is alternatively known as myeloid cell surface antigen CD33 and GP67. Human Siglec-3 cDNA encodes a 364 amino acid (aa) polypeptide with a hydrophobic signal peptide, an N-terminal Ig-like V-type domain, one Ig-like C2-type domains, a transmembrane region and a cytoplasmic tail (1, 4). Siglec-3 expression is restricted to cells of myelomonocytic lineage (2). It binds sialic acid preferring alpha 2,3-linkage over alpha 2,6-linkage (5). Studies indicated that Siglec-3 recruits SHP-1 and SHP-2 to its ITIMs (6, 7). When co‑cross‑linking with Fc gamma R1, Siglec3- inhibits tyrosine phosphorylation and calcium mobilization, suggesting Siglec-3 can mediate inhibitory signals (7).
- Crocker, P.R. and A. Varki (2001) Trends Immunol. 22:337.
- Crocker, P.R. and A. Varki (2001) Immunology 103:137.
- Angata, T. et al. (2002) J. Biol. Chem. 277:24466.
- Simmons, D. and B. Seed (1988) J. Immunol. 141:2797.
- Freeman, S.D. et al. (1995) Blood 85:2002.
- Taylor, V.C. et al. (1999) J. Biol. Chem. 274:11505.
- Ulyanova, T. et al. (1999) Eur. J. Immunol. 29:3440.
FAQs
-
Is this protein the wild-type or does it contain a mutation at amino acid 69 (R69G)?
The sequence of this protein is Met17-His259, with a C-terminal 6-His tag, and the full referenced sequence for the expressed protein can be found in the Accession section on the product page. This sequence does not contain the R69G natural variant mutation.
Reviews for Recombinant Human Siglec-3/CD33 His-tag Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human Siglec-3/CD33 His-tag Protein, CF and earn rewards!
Have you used Recombinant Human Siglec-3/CD33 His-tag Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image